KR20200008788A - Reagent composition for inhibiting Ninj1 comprising microRNA - Google Patents

Reagent composition for inhibiting Ninj1 comprising microRNA Download PDF

Info

Publication number
KR20200008788A
KR20200008788A KR1020180082895A KR20180082895A KR20200008788A KR 20200008788 A KR20200008788 A KR 20200008788A KR 1020180082895 A KR1020180082895 A KR 1020180082895A KR 20180082895 A KR20180082895 A KR 20180082895A KR 20200008788 A KR20200008788 A KR 20200008788A
Authority
KR
South Korea
Prior art keywords
ninj1
inhibiting
expression
mirna
group
Prior art date
Application number
KR1020180082895A
Other languages
Korean (ko)
Other versions
KR102095298B1 (en
Inventor
이효종
황수정
Original Assignee
인제대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인제대학교 산학협력단 filed Critical 인제대학교 산학협력단
Priority to KR1020180082895A priority Critical patent/KR102095298B1/en
Publication of KR20200008788A publication Critical patent/KR20200008788A/en
Application granted granted Critical
Publication of KR102095298B1 publication Critical patent/KR102095298B1/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/20Animals treated with compounds which are neither proteins nor nucleic acids
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/035Animal model for multifactorial diseases
    • A01K2267/0362Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/035Animal model for multifactorial diseases
    • A01K2267/0368Animal model for inflammation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • C12N2310/141MicroRNAs, miRNAs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a reagent composition for inhibiting Ninj1 comprising microRNA having an inhibitory effect on Ninjurin-1 (Ninj1) as an active ingredient and an inhibitory method. More specifically, it is confirmed that miR125a, miR145, miR184, miR206, and miR761 microRNA inhibit the expression of Ninj1 in phagocytes and inflammatory animal models and thus inhibit the expression of cytokines. Therefore, the composition comprising the microRNA as an active ingredient may be provided as a reagent composition for inhibiting Ninjurin-1(Ninj1).

Description

마이크로 RNA를 유효성분으로 함유하는 Ninj1 억제용 시약조성물{Reagent composition for inhibiting Ninj1 comprising microRNA}Reagent composition for inhibiting Ninj1 comprising microRNA containing micro RNA as an active ingredient

본 발명은 Ninj1(Ninjurin-1)억제 효과를 나타내는 마이크로 RNA를 유효성분으로 함유하는 Ninj1 억제용 시약조성물 및 억제 방법에 관한 것이다.The present invention relates to a reagent composition for inhibiting Ninj1 containing microRNA having an inhibitory effect on Ninj1 (Ninjurin-1) as an active ingredient, and a method for inhibiting the inhibition.

인간 Ninj1(Ninjurin-1)은 염색체(chromosome) 9q22에 위치하고 있으며 152개의 아미노산으로 구성되어 있다. 마우스 Ninj-1의 경우는 염색체 13에 위치하고 있으며 152개의 아미노산으로 구성되어 있다. Ninj-1 아미노산 서열(sequence) 에서 두 곳의 막 통과 영역(transmembrane domain)을 예측할 수 있다. 그리고 실험을 통하여 Ninj-1이 세포막에 위치한 단백질임이 알려져있다(Araki, T. & Milbrandt, J., Neuron 17, 353-361, 1996). 이러한 사실을 통해 Ninj-1의 N-말단(terminal) 영역이 길게 세포 밖으로 뻗어 나와 있을 것으로 추측할 수 있다.Human Ninj1 (Ninjurin-1) is located on chromosome 9q22 and consists of 152 amino acids. Mouse Ninj-1 is located on chromosome 13 and consists of 152 amino acids. Two transmembrane domains can be predicted from the Ninj-1 amino acid sequence. Experiments have shown that Ninj-1 is a protein located in cell membranes (Araki, T. & Milbrandt, J., Neuron 17, 353-361, 1996). This fact suggests that the N-terminal region of Ninj-1 may extend out of the cell.

Ninj-1은 동종 단백질 간의 결합이 알려져 있으며, 염증 환경 또는 다발성 경화증의 동물모델에서 그 발현율이 증가하고 암세포 및 면역세포의 이동성(motility) 과 내피세포 내 이동(transendothelial migration)에 주요하게 관여함이 알려져 있다. Ninj-1 is known to bind to homologous proteins, and its expression rate is increased in inflammatory environments or in animal models of multiple sclerosis, and is mainly involved in the motility and transendothelial migration of cancer cells and immune cells. Known.

이러한 Ninj-1은 다양한 조직에서 발현되고 있는데, RNA 단계에서는 심장(heart), 뇌(brain), 태반(placenta), 폐(lung), 간(liver), 골격근(sk.Muscle), 콩팥(kidney), 이자(pancreas), 비장(spleen), 흉선(thymus), 전립선(prostate), 고환(testis), 난소(ovary), 소장(sm.int.), 대장(colon), 혈액(blood), 부신(adrenal gland) 및 후근절(Dorsal Root Ganglia, DRG)에서 발현되고, 단백질 단계에서는 간, 콩팥, 흉선, 자궁(uterus), 부신, 망막(retina) 및 후근절에서 발현되는 것이 보고된 바 있다.Ninj-1 is expressed in various tissues.In the RNA stage, heart, brain, placenta, lung, liver, skeletal muscle (sk.Muscle) and kidney ), Pancreas, spleen, thymus, prostate, testis, ovary, small intestine, sm.int., Colon, blood, It has been reported in the adrenal gland and Dorsal Root Ganglia (DRG), and in the protein phase in the liver, kidneys, thymus, uterus, adrenal gland, retina, and dorsal root. .

이와 같이 Ninj-1이 광범위한 조직에서 발현되어 다양한 질환을 유도하는 것으로 확인됨에 따라, Ninj-1을 억제하는 효과를 나타낼 수 있는 약물 또는 치료방법은 염증을 포함하여 Ninj-1에 의해 유도되는 관련된 질환들을 예방하거나 치료하기 위한 새로운 치료 전략이 될 수 있다.As Ninj-1 is found to be expressed in a wide range of tissues to induce a variety of diseases, drugs or treatments that may have an effect of inhibiting Ninj-1 include related diseases induced by Ninj-1, including inflammation. It may be a new treatment strategy to prevent or treat them.

대한민국공개특허 제10-2010-0065953호(2010.06.17. 공개)Republic of Korea Patent Publication No. 10-2010-0065953 (Published June 17, 2010)

앞서 전술한 바와 같이 본 발명은 광범위한 조직에서 발현되어 다양한 질환을 유도하는 Ninj-1를 효과적으로 억제할 수 있는 마이크로 RNA를 유효성분으로 함유하는 조성물을 제공하여, Ninj-1 관련 신호전달과정 연구 및 Ninj-1에 의해 유도되는 관련 질환들의 치료제 또는 치료방법 연구를 위한 Ninj-1 억제용 시약조성물을 제공하고자 한다.As described above, the present invention provides a composition containing micro RNA as an active ingredient capable of effectively inhibiting Ninj-1, which is expressed in a wide range of tissues and induces various diseases, thereby studying Ninj-1 related signaling processes and Ninj The present invention provides a reagent composition for inhibiting Ninj-1 for the study of a therapeutic agent or method for treating related diseases induced by -1.

본 발명은 마이크로 RNA를 유효성분으로 함유하며, 상기 마이크로 RNA는 miR125a, miR145, miR184, miR206 및 miR761으로 이루어진 군에서 선택되는 것을 특징으로 하는 Ninj1(Ninjurin-1) 억제용 시약조성물을 제공한다.The present invention contains micro RNA as an active ingredient, the micro RNA provides a reagent composition for inhibiting Ninj1 (Ninjurin-1), characterized in that selected from the group consisting of miR125a, miR145, miR184, miR206 and miR761.

본 발명은 인간을 제외한 개체로부터 분리된 세포에 miR125a, miR145, miR184, miR206 및 miR761으로 이루어진 군에서 선택되는 마이크로 RNA를 처리하는 단계를 포함하는 생체 외(in vitro)에서 Ninj1를 억제하는 방법을 제공한다.The present invention provides a method of inhibiting Ninj1 in vitro comprising treating microRNAs selected from the group consisting of miR125a, miR145, miR184, miR206 and miR761 to cells isolated from individuals other than humans. do.

또한, 인간을 제외한 염증성 동물모델에 miR125a, miR145, miR184, miR206 및 miR761으로 이루어진 군에서 선택되는 마이크로 RNA를 처리하는 단계를 포함하는 생체 내(in vivo)에서 Ninj1을 억제하는 방법을 제공한다.In addition, the present invention provides a method of inhibiting Ninj1 in vivo, including treating microRNAs selected from the group consisting of miR125a, miR145, miR184, miR206, and miR761 in an inflammatory animal model other than human.

본 발명에 따르면, miR125a, miR145, miR184, miR206 및 miR761 마이크로 RNA가 대식세포 및 염증 동물모델에서 Ninj1 발현을 억제시켜 사이토카인의 발현을 억제시키는 것으로 확인됨에 따라, 상기 마이크로 RNA를 유효성분으로 함유하는 조성물은 Ninj1(Ninjurin-1) 억제용 시약조성물로 제공될 수 있으며, 상기 마이크로 RNA를 이용한 Ninj1(Ninjurin-1) 억제 방법이 제공될 수 있다.According to the present invention, as miR125a, miR145, miR184, miR206 and miR761 micro RNA was found to inhibit Ninj1 expression in macrophages and inflammatory animal models to inhibit the expression of cytokines, containing the micro RNA as an active ingredient The composition may be provided as a reagent composition for inhibiting Ninj1 (Ninjurin-1), and a method for inhibiting Ninj1 (Ninjurin-1) using the microRNA may be provided.

도 1은 Ninj1 발현 조절 효과를 나타낼 것으로 예상되는 마이크로 RNA를 동정하기 위해 수행된 miRNA PCR 분석결과이다.
도 2는 마이크로 RNA의 Ninj1 발현 조절효과를 확인한 결과로, 도 2A는 Raw 264.74 세포에서 miR125a-5p, miR145, miR184, miR206 및 miR761의 Ninj1 발현 억제 효과를 확인한 결과이며, 도 2B는 miRNA mimic 125a-5p의 농도 의존적 Ninj1 발현 억제 효과를 확인한 결과이다.
도 3은 마이크로 RNA가 Ninj1 하위 사이토카인 관련 유전자의 발현에 미치는 영향을 확인한 결과로, 도 3A는 LPS 처리된 Raw 264.74 세포군과 LPS 및 miRNA mimic 125a-5p를 함께 처리한 세포군에서 Ninj1 하위 사이토카인 관련 유전자의 발현을 확인한 결과이며, 도 3B는 Ninj1를 과발현시킨 세포군과 Ninj1가 과발현된 세포에 miRNA mimic 125a-5p를 처리한 세포군에서 Ninj1 하위 사이토카인 관련 유전자의 발현을 확인한 결과이다.
도 4는 마이크로 RNA의 대식세포 활성 저해 효과를 확인한 결과로, 각각 LPS 처리된 골수 유래 대식세포와 Raw 264.74 세포에 miRNA mimic 125a-5p를 처리하고 대식세포의 부착능을 확인한 결과이다.
도 5는 LPS로 염증이 유도된 마우스 동물모델에서 마이크로 RNA의 염증 억제효과를 확인한 결과로, 도 5A는 염증모델에서 miRNA mimic 125a-5p 처리에 의한 Ninj1 발현 수준을 확인한 PCR 분석결과이며, 도 5B는 염증모델에서 miRNA mimic 125a-5p 처리에 의한 Ninj1 발현 수준을 확인한 웨스턴블롯 분석결과이다.
도 6은 LPS로 염증이 유도된 마우스 동물모델의 안구조직에서 Ninj1 발현 수준을 확인한 형광염색결과이다.
도 7은 당뇨병성 망막증 동물모델에 20μM miR mimic 125a-5p를 처리한 실험군과 처리하지 않은 실험군에서 마이크로 RNA의 망막 손상 개선 효과를 확인한 결과로, 도 7A는 각 실험군의 안구에서 Ninj1 발현 수준을 확인한 PCR 분석결과이며, 도 7B는 각 실험군의 안구에서 튜불린 발현 수준을 확인한 PCR 분석결과이며, 도 7C는 각 실험군의 안구에서 Ninj1과 튜불린 발현 수준을 확인한 웨스턴블롯 분석결과이다.
도 8A는 각 실험군의 안구에서 덱스트란의 누출 정도로 당뇨에 의한 장벽손상을 확인한 FICT-덱스트란 염색결과와 망막의 전체, GCL, INL 및 ONL을 H&E 염색한 결과 및 Ninj1과 F4/80을 조직염색한 결과이며, 도 8B는 망막의 전체 두께와 GCL, INL 및 ONL 두께를 확인한 결과이다.
1 is a miRNA PCR analysis performed to identify the micro RNA expected to exhibit a Ninj1 expression regulatory effect.
2 is a result of confirming the control effect of Ninj1 expression of micro RNA, Figure 2A is a result confirming the inhibitory effect of Ninj1 expression of miR125a-5p, miR145, miR184, miR206 and miR761 in Raw 264.74 cells, Figure 2B is miRNA mimic 125a- The result of confirming the concentration dependent Ninj1 expression inhibitory effect of 5p.
FIG. 3 shows the effect of microRNA on the expression of Ninj1 subcytokine related genes. FIG. 3A is related to Ninj1 subcytokine in LPS-treated Raw 264.74 cell group and LPS- and miRNA mimic 125a-5p cell group. 3B shows the results of confirming the expression of the Ninj1 lower cytokine related genes in the cell group overexpressing Ninj1 and the cell group treated with miRNA mimic 125a-5p in the cells overexpressing Ninj1.
4 is a result of confirming the effect of inhibiting the macrophage activity of the microRNA, the result of treatment of miRNA mimic 125a-5p to LPS-treated bone marrow-derived macrophages and Raw 264.74 cells, respectively, and confirmed the adhesion of macrophages.
5 is a result of confirming the inflammation inhibitory effect of the micro RNA in the mouse animal model induced inflammation by LPS, Figure 5A is a PCR analysis result confirming the Ninj1 expression level by miRNA mimic 125a-5p treatment in the inflammation model, Figure 5B Is a Western blot analysis confirming the Ninj1 expression level by miRNA mimic 125a-5p treatment in the inflammation model.
6 is a fluorescence staining result confirming the Ninj1 expression level in the eye tissue of the mouse animal model induced inflammation by LPS.
7 is a result of confirming the effect of improving the retinal damage of the micro RNA in the experimental group and the 20 group treated with 20 μM miR mimic 125a-5p diabetic retinopathy animal model, Figure 7A confirms the Ninj1 expression level in the eye of each experimental group 7B is a PCR analysis result confirming the tubulin expression level in the eye of each experimental group, Figure 7C is a Western blot analysis result confirming the Ninj1 and tubulin expression level in the eye of each experimental group.
Figure 8A shows the results of FICT-dextran staining confirming diabetic barrier damage to the degree of dextran leakage in the eyes of each experimental group, H & E staining of the entire retina, GCL, INL and ONL, and tissue staining of Ninj1 and F4 / 80. 8B is a result of checking the total thickness of the retina and the thicknesses of GCL, INL, and ONL.

이하, 본 발명을 보다 상세하게 설명한다.Hereinafter, the present invention will be described in more detail.

본 발명은 마이크로 RNA를 유효성분으로 함유하며, 상기 마이크로 RNA는 miR125a, miR145, miR184, miR206 및 miR761으로 이루어진 군에서 선택되는 것을 특징으로 하는 Ninj1(Ninjurin-1) 억제용 시약조성물을 제공할 수 있다.The present invention contains micro RNA as an active ingredient, the micro RNA can provide a reagent composition for inhibiting Ninj1 (Ninjurin-1), characterized in that selected from the group consisting of miR125a, miR145, miR184, miR206 and miR761. .

상기 마이크로 RNA는 생체 외(in vitro)에서 대식세포 내 Ninj1 발현 또는 활성을 억제하여 대식세포의 활성을 저해시킬 수 있다.The micro RNA may inhibit the activity of macrophages by inhibiting Ninj1 expression or activity in macrophages in vitro.

상기 마이크로 RNA는 염증 동물모델의 생체 내(in vivo)에서 Ninj1 발현 또는 활성을 억제시킬 수 있다.The microRNA may inhibit Ninj1 expression or activity in vivo in an inflammatory animal model.

본 발명의 실시예에 따르면, Ninj1의 발현조절에 영향을 미칠 것으로 예상된 miR125a, miR145, miR184, miR206 및 miR761 마이크로 RNA가 실제로 Ninj1 및 사이토카인 관련 유전자의 발현에 미치는 영향을 확인하기 위해, Raw 264.7 세포에 대조군인 scramble RNA와 상기 마이크로 RNA에 대한 miRNA mimic을 형질주입한 후 LPS를 처리하여 Ninj1 발현에 대한 영향을 확인한 결과, 도 2A와 같이 동정한 miRNA mimic 모두 Ninj1 발현을 유의하게 감소시켰으며, 그 중 miRNA 125a-5p mimic의 효과가 가장 좋은 것으로 확인됨에 따라, 상기 miRNA 125a-5p mimic을 농도별로 처리하여 PCR 분석을 수행하였다.According to an embodiment of the present invention, in order to confirm the effect of miR125a, miR145, miR184, miR206 and miR761 microRNAs expected to affect the expression regulation of Ninj1 actually on the expression of Ninj1 and cytokine related genes, Raw 264.7 As a result of transfecting miRNA mimic to the microRNA and the scramble RNA as a control group, LPS treatment confirmed the effect on Ninj1 expression. As shown in FIG. 2A, both miRNA mimics significantly reduced Ninj1 expression. Among them, the miRNA 125a-5p mimic was found to have the best effect, and the miRNA 125a-5p mimic was treated by concentration to perform PCR analysis.

그 결과, 도 2B와 같이 miRNA 125a-5p mimic의 농도의존적으로 Ninj1의 발현이 감소되는 것을 확인할 수 있었다. 또한, miRNA 125a-5p mimic이 Ninj1 하위 사이토카인 관련 유전자들의 발현 조절에 영향을 미칠 수 있는지 확인한 결과, 도 3과 같이 LPS 처리군과 Ninj1 과발현군에서는 하위 사이토카인 관련 유전자들이 대부분 증가하였고, miRNA 125a-5p mimic 처리군에서는 하위 사이토카인의 발현이 모두 감소되는 것을 확인할 수 있었다.As a result, as shown in Figure 2B it was confirmed that the expression of Ninj1 is reduced depending on the concentration of miRNA 125a-5p mimic. In addition, as a result of confirming that miRNA 125a-5p mimic may influence the expression regulation of Ninj1 subcytokine related genes, as shown in FIG. 3, the subcytokine related genes were increased in the LPS-treated group and the Ninj1 overexpression group, and miRNA 125a was increased. In the -5p mimic treatment group, all the expressions of the lower cytokines were reduced.

상기 결과로부터 miRNA 125a-5p는 Ninj1의 발현을 조절함으로써, 그 하위 사이토카인 관련 유전자의 발현을 조절하는 것이 확인되었다.From the above results, it was confirmed that miRNA 125a-5p regulates the expression of Ninj1, thereby regulating the expression of its lower cytokine related genes.

이에 따라, 본 발명은 인간을 제외한 개체로부터 분리된 세포에 마이크로 RNA를 처리하는 단계를 포함하는 생체 외(in vitro)에서 Ninj1를 억제하는 방법을 제공할 수 있다.Accordingly, the present invention can provide a method for inhibiting Ninj1 in vitro, including treating microRNAs with cells isolated from individuals other than humans.

보다 상세하게 상기 세포는 대식세포일 수 있으며, 상기 마이크로 RNA는 miR125a, miR145, miR184, miR206 및 miR761으로 이루어진 군에서 선택될 수 있다.In more detail, the cell may be a macrophage, and the microRNA may be selected from the group consisting of miR125a, miR145, miR184, miR206, and miR761.

또한, 본 발명은 인간을 제외한 염증성 동물모델에 마이크로 RNA를 처리하는 단계를 포함하는 생체 내(in vivo)에서 Ninj1을 억제하는 방법을 제공할 수 있다.In addition, the present invention can provide a method for inhibiting Ninj1 in vivo, including the step of processing micro RNA in an inflammatory animal model other than human.

보다 상세하게 상기 마이크로 RNA는 miR125a, miR145, miR184, miR206 및 miR761으로 이루어진 군에서 선택될 수 있다.In more detail, the micro RNA may be selected from the group consisting of miR125a, miR145, miR184, miR206 and miR761.

이하, 본 발명의 이해를 돕기 위하여 실시예를 들어 상세하게 설명하기로 한다. 다만 하기의 실시예는 본 발명의 내용을 예시하는 것일 뿐 본 발명의 범위가 하기 실시예에 한정되는 것은 아니다. 본 발명의 실시예는 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.Hereinafter, examples will be described in detail to help understand the present invention. However, the following examples are merely to illustrate the content of the present invention is not limited to the scope of the present invention. The embodiments of the present invention are provided to more completely explain the present invention to those skilled in the art.

<< 실험예Experimental Example 1> 세포 배양 1> cell culture

Raw 264.7 세포를 ATCC에서 구입하여 5% CO2, 37℃ 조건에서 유지하였다.Raw 264.7 cells were purchased from ATCC and maintained at 5% CO 2, 37 ° C.

Raw 264.7 세포를 10% 태아소혈청(FBS) 및 1% 항생제(Invitrogen, Carlsbad, CA)가 포함된 DMEM(Dulbecco’s Modified Eagle’s Medium) 배지에서 배양하였다. Raw 264.7 cells were cultured in DMEM (Dulbecco's Modified Eagle's Medium) medium containing 10% fetal bovine serum (FBS) and 1% antibiotic (Invitrogen, Carlsbad, Calif.).

<< 실험예Experimental Example 2> 사이토카인 분석 2> Cytokine Analysis

무혈청 조건 배지(Serum-free conditioned media; SFCM)에 RayBio mouse cytokine antibody array C1000 (RayBiotech, Inc.)을 제조사의 설명서에 따라 적용시켰다. 간략하게, 막을 SFCM 1 ml로 하룻밤 동안 인큐베이트한 후 세척하고 바이오틴이 결합된 항-사이토카인과 다시 인큐베이트하였다.RayBio mouse cytokine antibody array C1000 (RayBiotech, Inc.) was applied in serum-free conditioned media (SFCM) according to the manufacturer's instructions. Briefly, membranes were incubated overnight with 1 ml of SFCM, washed and incubated again with biotin bound anti-cytokines.

그 후, 막을 HRP가 결합된 스트렙트아비딘 2차 항체와 인큐베이트하여 시각화하고 화학발광(FUSION-SL4, Vilber)을 검출하였다.The membrane was then visualized by incubating with HRP-bound streptavidin secondary antibody and detecting chemiluminescence (FUSION-SL4, Vilber).

<< 실험예Experimental Example 3> 마이크로 RNA 실시간 정량적  3> Micro RNA Real Time Quantitative PCRPCR 분석 analysis

Hybrid-RTM micro RNA isolation kit (GeneAll®)를 이용하여 제조사의 설명서에 따라, 절개된 안구 또는 배양된 세포로부터 miRNA를 정제하였으며, miScript reverse trnascription kit (Qiagen Inc.)를 이용하여 제조사의 설명서에 따라, 분리된 200ng miRNAs를 합성하였다.According to the manufacturer's instructions using the Hybrid-RTM micro RNA isolation kit (GeneAll ® ), miRNAs were purified from the dissected eye or cultured cells, and according to the manufacturer's instructions using the miScript reverse trnascription kit (Qiagen Inc.). , 200ng miRNAs were synthesized.

그 후, miScript SYBR green PCR kit (Qiagen Inc.)를 이용하여 타겟 miRNA 프리아머와 함께 실시간 PCR를 수행하였다. miRNA PCR을 위해 cDNA 200 ng를 20 ng로 희석하였다. Thereafter, real-time PCR was performed with a target miRNA primer using a miScript SYBR green PCR kit (Qiagen Inc.). 200 ng of cDNA was diluted to 20 ng for miRNA PCR.

표준화 대조군으로 제공된 U6 짧은 RNA와 함께 miRNAs를 정량하였다.MiRNAs were quantified with U6 short RNA served as a standardized control.

miRNA 프라이머의 염기서열은 하기 표 1과 같다. Base sequences of miRNA primers are shown in Table 1 below.

열 주기 조건은 95℃에서 15분 후 94℃에서 15초, 55℃에서 30초 및 70℃에서 30초간 40주기로 진행되었다. 사이클 임계값은 in vivo 및 in vitro 샘플에서 대한 자동 기준선 및 0.1 임계값을 이용하여 계산하였다.Heat cycle conditions were followed by 40 cycles of 15 seconds at 95 ° C., 15 seconds at 94 ° C., 30 seconds at 55 ° C., and 30 seconds at 70 ° C. Cycle thresholds were calculated using automatic baseline and 0.1 thresholds for in vivo and in vitro samples.

miRNAmiRNA accession numberaccession number 프라이머 염기서열Primer Sequence miR-1amiR-1a MI0000139 MI0000139 3'-TGGAATGTAAAGAAGTATGTAT-5'3'-TGGAATGTAAAGAAGTATGTAT-5 ' miR-206-3pmiR-206-3p MIMAT0000239MIMAT0000239 3'-TGGAATGTAAGGAAGTGTGTGG-5'3'-TGGAATGTAAGGAAGTGTGTGG-5 ' miR-184-3pmiR-184-3p MIMAT0000213MIMAT0000213 3'-TGGACGGAGAACTGATAAGGGT-5'3'-TGGACGGAGAACTGATAAGGGT-5 ' miR-34amiR-34a MI0000584MI0000584 3'-TGGCAGTGTCTTAGCTGGTTGT-5'3'-TGGCAGTGTCTTAGCTGGTTGT-5 ' miR-145a-5pmiR-145a-5p MIMAT0000157MIMAT0000157 3'-GTCCAGTTTTCCCAGGAATCCCT-5'3'-GTCCAGTTTTCCCAGGAATCCCT-5 ' miR-214miR-214 MI0000698MI0000698 3'-ACAGCAGGCACAGACAGGCAGT-5'3'-ACAGCAGGCACAGACAGGCAGT-5 ' miR-761miR-761 MI0004306MI0004306 3'-GCAGCAGGGTGAAACTGACACA-5'3'-GCAGCAGGGTGAAACTGACACA-5 ' miR-125a-5pmiR-125a-5p MIMAT0000135MIMAT0000135 3'-TCCCTGAGACCCTTTAACCTGTGA-5'3'-TCCCTGAGACCCTTTAACCTGTGA-5 ' miR-378miR-378 MI0000795MI0000795 3'-ACTGGACTTGGAGTCAGAAGG-5'3'-ACTGGACTTGGAGTCAGAAGG-5 ' miR-449cmiR-449c MI0004645MI0004645 3'-AGGCAGTGCATTGCTAGCTGG-5'3'-AGGCAGTGCATTGCTAGCTGG-5 ' miR-338-3pmiR-338-3p MIMAT0000582MIMAT0000582 3'-TCCAGCATCAGTGATTTTGTTG-5'3'-TCCAGCATCAGTGATTTTGTTG-5 '

<< 실험예Experimental Example 4>  4> miRNAmiRNA mimic 형질주입 mimic transfection

miRNAs의 과발현 또는 억제를 위해, miRNA mimics (miR-125a-5p, #MSY0000135; miR-145a-5p, #MSY0000157; miR-184-3p, #MSY0000213; miR-761, #MSY0003893; miR-206-3p, #MSY0000239, Qiagen, Valencia, CA, USA)을 리포펙타민 2000 (Invitrogen)을 이용하여 제조사의 설명서에 따라 형질주입하였다.For overexpression or inhibition of miRNAs, miRNA mimics (miR-125a-5p, # MSY0000135; miR-145a-5p, # MSY0000157; miR-184-3p, # MSY0000213; miR-761, # MSY0003893; miR-206-3p , # MSY0000239, Qiagen, Valencia, CA, USA) were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.

<< 실험예Experimental Example 5>  5> 웨스턴Weston 블롯Blot

웨스턴 블롯을 위해, 40mM Tris-cl (pH 7.4), 10mM EDTA, 120mM Nacl, 0.1% NP-40, 1mM PMSF, 2 μg/ml 류펩틴이 포함된 용해 버퍼를 이용하여 샘플을 용해시켰다. 용해물을 10% SDS-PAGE로 분리시키고 니트로셀룰로스 막으로 옮겼다.For western blots, samples were dissolved using lysis buffer containing 40 mM Tris-cl (pH 7.4), 10 mM EDTA, 120 mM Nacl, 0.1% NP-40, 1 mM PMSF, 2 μg / ml leupeptin. Lysates were separated by 10% SDS-PAGE and transferred to nitrocellulose membrane.

막을 0.5% 트윈 20 및 5% 탈지분유가 포함된 인산염완충용액(TBS; 10 mM Tris-Cl pH 7.4)로 블로킹하고 블로킹 용액에 포함된 1차 특이적 항체로 4℃에서 하룻밤 동안 인큐베이트한 후 세척하고 실온에서 1시간 동안 2차 항체와 인큐베이트하였다. 각 단백질 밴드를 화학발광(FUSION-SL4, Vilber)시켜 검출하였다.The membrane was blocked with phosphate buffer solution (TBS; 10 mM Tris-Cl pH 7.4) containing 0.5% Tween 20 and 5% skim milk powder and incubated overnight at 4 ° C. with a primary specific antibody included in the blocking solution. Washed and incubated with secondary antibody for 1 hour at room temperature. Each protein band was detected by chemiluminescence (FUSION-SL4, Vilber).

<< 실험예Experimental Example 6> 골수에서  6> In the bone marrow 유래된Derived 대식세포( Macrophage ( BMDMBMDM ) 분리) Separation

골수에서 유래된 대식세포를 10주령 C57BL/6 tm1a/tm1a 생쥐와 10주령 10-Week-old C57BL/6 야생형 타입 생쥐의 대퇴골 및 경골에서 분리하였다.Bone marrow-derived macrophages were isolated from the femur and tibia of 10-week-old C57BL / 6 tm1a / tm1a mice and 10-week-old 10-Week-old C57BL / 6 wild-type mice.

분리된 골수 유래 대식세포를 10% FBS 및 1% 항생제가 포함된 RPMI 1640 배지에서 4시간 동안 배양한 후 골수 유래 대식세포 분화를 위해, 20ng/ml 대식세포 콜로니 자극 인자(macrophage-colony stimulating factor; cat no. Peprotech 315-02)를 배지에 첨가하여 7일간 배양하였다.The isolated bone marrow-derived macrophages were cultured in RPMI 1640 medium containing 10% FBS and 1% antibiotics for 4 hours, and then, for bone marrow-derived macrophage differentiation, 20ng / ml macrophage-colony stimulating factor; cat no.Peprotech 315-02) was added to the medium and incubated for 7 days.

<< 실험예Experimental Example 7> 부착 분석 7> Attachment Analysis

세포 접종 전날 96 웰 플레이트의 각 웰에 ECMs의 구성성분인 5 μg/ml 피브로넥틴 (cat no. gibco 33010-018), 10 μg/ml 콜라겐 타입 I (cat no. BD 354249), 10 μg/ml 라미닌 (cat no. sc-29012) 및 5 μg/ml 젤라틴 (cat no. sigma G1890)으로 4℃에서 24시간 동안 코팅하고 다음날 세척 버퍼(0.1 % BSA in medium)로 2시간 동안 세척하였다.5 μg / ml fibronectin (cat no. Gibco 33010-018), 10 μg / ml collagen type I (cat no. BD 354249), 10 μg / ml laminin, constituents of ECMs, in each well of a 96 well plate the day before cell inoculation (cat no. sc-29012) and 5 μg / ml gelatin (cat no. sigma G1890) were coated at 4 ° C. for 24 hours and washed the next day with washing buffer (0.1% BSA in medium) for 2 hours.

블로킹 버퍼(0.5% BSA in medium)를 각 웰에 첨가고 37℃에서 60분간 인큐베이션한 후 세척버퍼로 다시 한번 세척하고 4℃에서 96 웰 플레이트를 유지시켰다.Blocking buffer (0.5% BSA in medium) was added to each well and incubated at 37 ° C. for 60 minutes, then washed again with a wash buffer and maintained at 96 ° C. in a 96 well plate.

웰 당 2×104 세포로 계수하여 각 웰에 분주하고 세척 버퍼로 세포를 세척한 후 4% PFA로 10분간 고정시켰다.Count wells at 2 × 10 4 cells per well, dispense into each well, wash cells with wash buffer and fix for 10 min with 4% PFA.

세포를 바닥에 부착시키고 5 mg/ml 크리스탈 바이올렛으로 염색한 후 하루 동안 건조시켰다. 다음날, 1% SDS 100 μl를 각 웰에 첨가하여 실온에서 30분간 인큐베이트한 후 550 nm에서 ELISA 분석을 수행하였다.Cells were attached to the bottom, stained with 5 mg / ml crystal violet and dried for one day. The following day, 100 μl of 1% SDS was added to each well, incubated for 30 minutes at room temperature, followed by ELISA analysis at 550 nm.

<< 실험예Experimental Example 8> 동물실험 8> Animal Experiment

1. One. 엔도톡신으로With endotoxin 유도된 염증 동물모델 제작 Induced Inflammation Animal Model

7 주령 C57BL/6 야생형 생쥐에게 6.6 μg LPS (330 μg/kg of body weight)를 4일동안 3번 복강 내 주사하였으며, 20 μM miRNA mimic은 리포펙타민 2000을 이용하여 안구에 혈관 내 주사하였다. Seven-week-old C57BL / 6 wild-type mice were injected intraperitoneally with 6.6 μg LPS (330 μg / kg of body weight) three times over 4 days, and 20 μM miRNA mimic was intravenously injected into the eye using lipofectamine 2000.

마지막 LPS 처리 24시간 후 안락사시켰다.Euthanasia was performed 24 hours after the last LPS treatment.

2. 2. 스트렙토조토신(STZ)로With streptozotocin (STZ) 유도된 당뇨병 동물모델 제작 Induced Diabetes Animal Model

당뇨병 생쥐 모델은 일회, 고용량의 스트렙토조토신(STZ; Sigma, S0130)이 췌장의 베타 세포에 독성을 일으키는 방법으로 유도되었다. 8주령 수컷 C57BL/6 생쥐 및 스트렙토조토신에 매우 민감한 ICR 생쥐를 이용하여 스트렙토조토신에 의해 유도된 당뇨병 모델을 개발하였다.In the diabetic mouse model, a single, high dose of streptozotocin (STZ; Sigma, S0130) was induced by the toxicity of pancreatic beta cells. A model of diabetes induced by streptozotocin was developed using 8-week-old male C57BL / 6 mice and ICR mice that were highly sensitive to streptozotocin.

STZ 처리 4시간 전부터 모든 동물에게 음식 없이 오직 물만 공급하였다.Four hours before STZ treatment, all animals were fed with no water and only water.

C57BL/6 생쥐 실험군에는 50 mM 시트레이트 버퍼(pH4.5)에 용해시킨 STZ을 180mg/kg의 일회량으로 복강내로 주입하였으며, ICR 생쥐에게는 50 mM 시트레이트 버퍼(pH4.5)에 용해시킨 STZ을 100 mg/kg의 일회량으로 복강내 주입하였다.The experimental group of C57BL / 6 mice was intraperitoneally injected with 180 mg / kg of STZ dissolved in 50 mM citrate buffer (pH4.5), and IZ mice were dissolved in 50 mM citrate buffer (pH4.5). Was injected intraperitoneally in a single dose of 100 mg / kg.

또한, 대조군으로 동일한 용량의 50 mM 시트레이트 버퍼(pH4.5)를 복강 내 주사하였다. 복부 주사가 완료된 후 정상적으로 음식을 공급하였다.In addition, the control group was injected intraperitoneally with the same dose of 50 mM citrate buffer (pH 4.5). Food was normally supplied after the abdominal injection was completed.

이때, 치명적인 저혈당증에 의한 폐사를 예방하기 위해 10% 수크로스를 3일 동안 물 대신 공급하였으며, 4일째에 공복혈당 250 mg/dL인 생쥐만을 선택하여 실험에 사용하였다. At this time, 10% sucrose was supplied instead of water for 3 days to prevent death due to fatal hypoglycemia, and on day 4, only mice having fasting glucose of 250 mg / dL were used for the experiment.

3. 3. miRNAmiRNA mimic의  mimic 안구내Intraocular 주사 injection

당뇨병 10주 후, 20μM miR mimic 125a-5p가 첨가된 리포펙타민을 ICR 생쥐의 안구속으로 주사하였다.After 10 weeks of diabetes, lipofectamine with 20 μM miR mimic 125a-5p was injected into the eye of ICR mice.

<< 실험예Experimental Example 9> 플루오레세인( 9> Fluorescein ( FITCFITC )-덱스트란 관류) -Dextran perfusion

25 mg/ml FITC-덱스트란(70kDa)을 꼬리 정맥을 통하여 관류시키고 형광현미경하에서 망막평면 표본고정을 확인하였다.25 mg / ml FITC-dextran (70kDa) was perfused through the tail vein and the retinal plane fixation was confirmed under fluorescence microscopy.

<< 실시예Example 1>  1> Ninj1의Ninj1's 발현을 조절하는  Regulating expression miRNAmiRNA 확인 Confirm

Ninjurin1 발현이 가장 높은 시기인 5일령 안구(A)와 LPS에 의해 자극된 Raw 264.7 세포(B)에서 miRNA의 발현 차이를 확인하기 위해 PCR 분석을 수행하였다.PCR analysis was performed to identify the difference in miRNA expression in 5-day-old eyes (A) and LPS-stimulated Raw 264.7 cells (B).

그 결과, 도 1과 같이 두 조건에서 일관성 있게 발현차이를 나타낸 miR125a, miR145, miR184, miR206 및 miR761은 Ninj1 상위 조절 인자로 제안될 수 있다.As a result, miR125a, miR145, miR184, miR206 and miR761, which showed consistent expression differences in two conditions as shown in FIG. 1, may be proposed as Ninj1 higher regulatory factors.

<< 실시예Example 2>  2> miRNAmiRNA mimic의  mimic Ninj1Ninj1 저해 효과 및 사이토카인 관련 유전자 발현에 미치는 영향 확인 Identification of inhibitory effect and effect on cytokine-related gene expression

앞서 확인된 마이크로 RNA가 Ninj1 및 사이토카인 관련 유전자의 발현에 미치는 영향을 확인하기 위해, Raw 264.7 세포에 대조군인 scramble RNA와 상기 마이크로 RNA에 대한 miRNA mimic을 형질주입한 후 LPS를 처리하여 Ninj1 발현에 대한 영향을 확인하였다. To confirm the effect of the microRNAs identified above on the expression of Ninj1 and cytokine related genes, raw 264.7 cells were transfected with control scramble RNA and miRNA mimic for the microRNA, and then treated with LPS for Ninj1 expression. The effect was confirmed.

그 결과, 도 2A와 같이 동정한 miRNA mimic 모두 Ninj1 발현을 유의하게 감소시켰으며, 그 중 miRNA 125a-5p mimic의 효과가 가장 좋은 것으로 확인됨에 따라, 상기 miRNA 125a-5p mimic을 농도별로 처리하여 PCR 분석을 수행하였다.As a result, all miRNA mimics identified as shown in FIG. 2A significantly reduced Ninj1 expression, and among them, miRNA 125a-5p mimics were found to have the best effect, and the miRNA 125a-5p mimics were treated by concentration to PCR. The analysis was performed.

그 결과, 도 2B와 같이 miRNA 125a-5p mimic의 농도의존적으로 Ninj1의 발현이 감소되는 것을 확인할 수 있었다.As a result, as shown in Figure 2B it was confirmed that the expression of Ninj1 is reduced depending on the concentration of miRNA 125a-5p mimic.

또한, miRNA 125a-5p mimic이 Ninj1 하위 사이토카인 관련 유전자들의 발현 조절에 영향을 미칠 수 있는지 확인하였다.In addition, we confirmed whether miRNA 125a-5p mimic can influence the expression regulation of Ninj1 subcytokine related genes.

그 결과, 도 3과 같이 LPS 처리군과 Ninj1 과발현군에서는 하위 사이토카인 관련 유전자들이 대부분 증가하였고, miRNA 125a-5p mimic 처리군에서는 하위 사이토카인의 발현이 모두 감소되는 것을 확인할 수 있었다.As a result, as shown in FIG. 3, the LPS-treated group and the Ninj1 over-expressed group mostly increased the lower cytokine-related genes, and the miRNA 125a-5p mimic treated group reduced all the expression of the lower cytokine.

상기 결과로부터 miRNA 125a-5p는 Ninj1의 발현을 조절함으로써, 그 하위 사이토카인 관련 유전자의 발현을 조절하는 것이 확인되었다.From the above results, it was confirmed that miRNA 125a-5p regulates the expression of Ninj1, thereby regulating the expression of its lower cytokine related genes.

<< 실시예Example 3>  3> miRNA의miRNA 대식세포 활성 저해 효과 확인 Inhibition of macrophage activity

대식세포의 주요기능 중 하나인 부착능을 이용하여 miRNA가 대식세포에 미치는 영향을 확인하기 위해, 부착 분석을 수행하여 miRNA mimic에 의한 대식세포 부착능 변화를 확인하였다.In order to confirm the effect of miRNA on macrophages using adhesion, one of the main functions of macrophages, adhesion analysis was performed to confirm the change of macrophage adhesion by miRNA mimic.

실험 전날 96 웰 플레이트를 ECM 성분인 콜라겐, 피브로넥틴, 라민, 젤라틴으로 코팅한 후 골수에서 유도된 대식세포(BMDM)와 Raw 264.7 세포의 부착 정도를 확인하였다. On the day before the experiment, 96-well plates were coated with ECM components collagen, fibronectin, lamin and gelatin, and then the degree of adhesion of BMDM-derived raw 264.7 cells to bone marrow was confirmed.

그 결과, 도 4와 같이 LPS가 처리된 두 세포 모두에서 부착능이 유의성있게 증가하였으나, miRNA mimic 125a이 처리된 세포군에서는 부착능 감소가 유의성있게 확인되었다.As a result, as shown in FIG. 4, the adhesion capacity was significantly increased in both LPS-treated cells, but in the cell group treated with miRNA mimic 125a, a decrease in adhesion was significantly confirmed.

상기 결과로부터 miRNA mimic 125a가 대식세포의 부착능을 감소시키는 효과를 나타내는 것이 확인되었다.From the above results, it was confirmed that miRNA mimic 125a exhibited an effect of reducing the adhesion of macrophages.

<< 실시예Example 4> 염증모델에서  4> Inflammation model miRNA의miRNA 염증억제 효과 확인 Inflammation inhibitory effect

miRNA의 생체 내 효과를 확인하기 위해, LPS에 의해 자극된 염증 마우스 모델을 사용하였다. 상기 모델은 LPS를 4일 동안 매일 복강내 주사하여 염증을 유도시킨 후 마우스 눈에 miRNA를 유리체강 내 주입한 후 염증모델 마우스의 안구를 적출하여 실시간 PCR과 웨스턴 블롯 분석을 수행하여 확인하였다.To confirm the in vivo effects of miRNAs, an inflammatory mouse model stimulated by LPS was used. The model was confirmed by performing intraperitoneal injection of LPS daily for 4 days to induce inflammation, injecting miRNA into the mouse's eye in the vitreous cavity, and then extracting the eyeballs of the inflammatory model mice and performing real-time PCR and western blot analysis.

그 결과, 도 5와 같이 LPS군에서는 Ninj1이 유의성있게 증가한 반면, miRNA mimic 125a가 처리된 군에서는 발현이 감소되는 것으로 나타났다. As a result, Ninj1 significantly increased in the LPS group as shown in FIG. 5, whereas expression was decreased in the miRNA mimic 125a-treated group.

또한, 안구조직으로 OCT 블록을 제작한 후 Ninj1 형광염색한 결과, 도 6과 같이 상기 결과와 동일하게 LPS군에서 발현이 증가된 Ninj1가 miRNA mimic 125a 처리군에서는 감소되는 것을 확인할 수 있었다.In addition, as a result of Ninj1 fluorescence staining after producing the OCT block in the eye tissue, it was confirmed that Ninj1 increased expression in the LPS group in the miRNA mimic 125a treatment group as shown in FIG.

상기 결과로부터 miRNA mimic 125a은 LPS로 유도된 염증 마우스 모델에서도 Ninj1 저해 효과를 나타나는 것이 확인되었다.From the above results, it was confirmed that miRNA mimic 125a showed Ninj1 inhibitory effect even in LPS-induced inflammatory mouse model.

<< 실시예Example 5> 당뇨병 망막증 모델에서  5> in diabetic retinopathy model miRNAmiRNA 효과 확인 Check the effect

눈에는 뇌와 마찬가지로 혈관-조직장벽인 blood-retinal barrier (BRB)가 존재하며, 당뇨병성 망막질환이 발병하게 되면, 이 장벽이 손상되면서 외부물질의 조직내 유입이 증가하고 심각한 염증반응이 나타난다. 이 과정에서 대식세포가 염증을 매개하고 장벽을 약화시키는 것으로 알려져있다. Like the brain, the eye has a blood-retinal barrier (BRB), which is a blood vessel-tissue barrier. When diabetic retinopathy develops, the barrier is damaged, increasing the inflow of foreign substances into the tissue, and a serious inflammatory reaction occurs. In this process, macrophages are known to mediate inflammation and weaken the barrier.

이에 따라, Ninj1의 발현을 조절하는 miRNA가 손상을 완화시킬 수 있는지 확인하기 위해, 형광물질 FITC가 태깅된 덱스트란을 투여한 후, 플랫 마운트에서 관찰하여 BRB의 손상 정도를 확인하였다. Accordingly, in order to confirm whether miRNA that regulates the expression of Ninj1 can alleviate the damage, after administering dextran tagged with the fluorescent material FITC, the degree of damage of BRB was confirmed by observation in a flat mount.

또한, Ninj1의 발현을 확인하기 위해, 실시간 PCR 및 웨스턴블롯을 수행하였으며, 마지막으로 H&E 염색과 Ninj1 및 F4/80을 조직염색하였다.In addition, to confirm the expression of Ninj1, real-time PCR and western blot were performed, and finally, H & E staining and tissue staining of Ninj1 and F4 / 80.

그 결과, 표 2와 같이 정상대조군과 비교하여 당뇨군에서 마우스의 몸무게가 현저하게 감소하고 고혈당을 유지하였으며, HbA1c가 8%로 증가됨에 따라 당뇨가 유발된 것을 확인할 수 있었으며, 마우스 안구로 실시간 PCR 및 웨스턴 블롯을 수행한 결과, 도 7A 내지 7C와 같이 Ninj1이 당뇨군(DM)에서 유의성있게 증가하였고, miRNA mimic 처리군에서는 유의성있는 감소가 나타났다.As a result, as shown in Table 2, compared to the normal control group, the weight of the mouse was significantly reduced and the hyperglycemia was maintained in the diabetic group, and it was confirmed that diabetes was induced as the HbA1c increased to 8%. As a result of performing the Western blot, Ninj1 significantly increased in the diabetic group (DM) as shown in FIGS. 7A to 7C, and showed a significant decrease in the miRNA mimic treatment group.

한편, 정맥주사로 FITC 덱스트란을 주입한 후, 안구를 적출하고 flat mount로 펼쳐서 형광현미경으로 확인한 결과, 도 8A 및 도 8B를 참고하면, 당뇨군에서는 장벽이 손상되어 덱스트란의 누출이 확인된 반면, miRNA mimic 처리군에서는 당뇨군에 비해 누출이 현저하게 감소된 것을 확인할 수 있었다. On the other hand, after injecting FITC dextran by intravenous injection, eyeballs were extracted and unfolded with a flat mount and confirmed by fluorescence microscopy. Referring to FIGS. On the other hand, the miRNA mimic treatment group was confirmed that the leakage was significantly reduced compared to the diabetic group.

또한, 안구조직을 H&E로 염색한 결과에서도 망막의 전체 두께와 GCL, INL 및 ONL 두께가 당뇨군에서 감소되고 miRNA mimic 처리군 군에서 유의하게 증가하는 것을 확인하였으며, 마지막으로 Ninj1과 F4/80을 조직염색한 결과, 당뇨군에서 Ninj1 발현과 대식세포의 수가 증가하였으나, miRNA mimic 처리군에서는 대식세포 수 감소가 나타났다.In addition, the results of H & E staining of the eye tissue showed that the total thickness of the retina, GCL, INL and ONL thickness were decreased in the diabetic group and significantly increased in the miRNA mimic treatment group. Finally, Ninj1 and F4 / 80 were identified. As a result of tissue staining, the expression of Ninj1 and the number of macrophages were increased in the diabetic group, but the number of macrophages was decreased in the miRNA mimic treatment group.

상기 결과로부터 miRNA mimic은 당뇨병이 유도된 동물모델에서도 Ninj1을 조절하고, Ninj1이 매개하는 당뇨병성 망막증을 개선하는 것이 확인되었다.The results showed that miRNA mimic regulates Ninj1 and improves Ninj1-mediated diabetic retinopathy in diabetic animal models.

Figure pat00001
Figure pat00001

이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.Having described the specific part of the present invention in detail, it is apparent to those of ordinary skill in the art that such a specific description is merely a preferred embodiment, thereby not limiting the scope of the present invention. something to do. Therefore, the substantial scope of the present invention will be defined by the appended claims and their equivalents.

Claims (5)

마이크로 RNA를 유효성분으로 함유하며, 상기 마이크로 RNA는 miR125a, miR145, miR184, miR206 및 miR761으로 이루어진 군에서 선택되는 것을 특징으로 하는 Ninj1(Ninjurin-1) 억제용 시약조성물.It contains micro RNA as an active ingredient, the micro RNA is a reagent composition for inhibiting Ninj1 (Ninjurin-1), characterized in that selected from the group consisting of miR125a, miR145, miR184, miR206 and miR761. 청구항 1에 있어서, 상기 마이크로 RNA는 생체 외(in vitro)에서 대식세포 내 Ninj1 발현 또는 활성을 억제하여 대식세포의 활성을 저해시키는 것을 특징으로 하는 Ninj1 억제용 시약조성물.The reagent composition for inhibiting Ninj1 of claim 1, wherein the microRNA inhibits the activity of macrophages by inhibiting Ninj1 expression or activity in macrophages in vitro. 청구항 1에 있어서, 상기 마이크로 RNA는 염증 동물모델의 생체 내(in vivo)에서 Ninj1 발현 또는 활성을 억제시키는 것을 특징으로 하는 Ninj1 억제용 시약조성물.The reagent composition for inhibiting Ninj1 according to claim 1, wherein the micro RNA inhibits Ninj1 expression or activity in vivo in an inflammatory animal model. 인간을 제외한 개체로부터 분리된 세포에 miR125a, miR145, miR184, miR206 및 miR761으로 이루어진 군에서 선택되는 마이크로 RNA를 처리하는 단계를 포함하는 생체 외(in vitro)에서 Ninj1를 억제하는 방법.A method of inhibiting Ninj1 in vitro comprising treating micronuclear cells selected from the group consisting of miR125a, miR145, miR184, miR206 and miR761 to cells isolated from individuals other than humans. 인간을 제외한 염증성 동물모델에 miR125a, miR145, miR184, miR206 및 miR761으로 이루어진 군에서 선택되는 마이크로 RNA를 처리하는 단계를 포함하는 생체 내(in vivo)에서 Ninj1을 억제하는 방법.A method of inhibiting Ninj1 in vivo, comprising treating a microRNA selected from the group consisting of miR125a, miR145, miR184, miR206, and miR761 in an inflammatory animal model other than human.
KR1020180082895A 2018-07-17 2018-07-17 Reagent composition for inhibiting Ninj1 comprising microRNA KR102095298B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020180082895A KR102095298B1 (en) 2018-07-17 2018-07-17 Reagent composition for inhibiting Ninj1 comprising microRNA

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020180082895A KR102095298B1 (en) 2018-07-17 2018-07-17 Reagent composition for inhibiting Ninj1 comprising microRNA

Publications (2)

Publication Number Publication Date
KR20200008788A true KR20200008788A (en) 2020-01-29
KR102095298B1 KR102095298B1 (en) 2020-03-31

Family

ID=69322362

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020180082895A KR102095298B1 (en) 2018-07-17 2018-07-17 Reagent composition for inhibiting Ninj1 comprising microRNA

Country Status (1)

Country Link
KR (1) KR102095298B1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100065953A (en) 2008-12-09 2010-06-17 서울대학교산학협력단 Composition comprising expression or activity inhibitors of ninjurin1 for the prevention and treatment of inflammatory disease
CN101843632A (en) * 2009-03-24 2010-09-29 复旦大学附属华山医院 Application of miR-145 in preparing medicament for treating inflammation
CN102018963A (en) * 2009-09-11 2011-04-20 中国科学院上海生命科学研究院 MiR-125a for adjusting regulated on activation normal T cell expressed and secreted (RANTES) expressions as well as composition and application thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100065953A (en) 2008-12-09 2010-06-17 서울대학교산학협력단 Composition comprising expression or activity inhibitors of ninjurin1 for the prevention and treatment of inflammatory disease
CN101843632A (en) * 2009-03-24 2010-09-29 复旦大学附属华山医院 Application of miR-145 in preparing medicament for treating inflammation
CN102018963A (en) * 2009-09-11 2011-04-20 中国科学院上海生命科学研究院 MiR-125a for adjusting regulated on activation normal T cell expressed and secreted (RANTES) expressions as well as composition and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
논문1:Int J Oncol. 2016 *

Also Published As

Publication number Publication date
KR102095298B1 (en) 2020-03-31

Similar Documents

Publication Publication Date Title
Li et al. Regulatory T-cells regulate neonatal heart regeneration by potentiating cardiomyocyte proliferation in a paracrine manner
US10870852B2 (en) Compositions and methods for treating diabetic retinopathy
CN102459576A (en) Compositions and methods for modulating stem cells and uses thereof
Kim et al. Xk‐related protein 8 regulates myoblast differentiation and survival
Fan et al. Pigment epithelium‐derived factor peptide promotes limbal stem cell proliferation through hedgehog pathway
CN110167564B (en) Modulation of tjp1 expression to modulate cardiac cell regeneration
Guo et al. PPP1CA/YAP/GS/Gln/mTORC1 pathway activates retinal Müller cells during diabetic retinopathy
EP2009100B1 (en) siRNA SPECIFIC TO WT1 17AA(-)ISOFORM AND USE THEREOF
KR20120089996A (en) New use of periostin
CN108601810B (en) Epicardial-derived paracrine factors for repairing cardiac tissue
US20080227745A1 (en) Methods and compositions for soluble CPG15
Yu et al. Ebp1 regulates myogenic differentiation of myoblast cells via SMAD 2/3 signaling pathway
KR102095298B1 (en) Reagent composition for inhibiting Ninj1 comprising microRNA
Gu et al. Sprouty1 regulates neuritogenesis and survival of cortical neurons
Zhou et al. Myostatin promotes the epithelial‐to‐mesenchymal transition of the dermomyotome during somitogenesis
Neu et al. Differential expression of entactin-1/nidogen-1 and entactin-2/nidogen-2 in myogenic differentiation
US20180153961A1 (en) Composition comprising ka11 polypeptide or gene encoding the same for inhibiting angiogenesis, and use thereof
JP6194517B2 (en) Neuronal differentiation promoter
KR20140143880A (en) Composition for Inhibiting Senescence of Adult Stem Cells By Increasing of miRNA Expression
Orieux et al. The protein tyrosine phosphatase interacting protein 51 (PTPIP51) is required for the differentiation of photoreceptors
KR102100490B1 (en) Gene and Cell therapy using cell fusion technology and use thereof
WO2022176917A1 (en) Mesenchymal stem cells and adipocytes for preparing mitokine mixture, and therapeutic or prophylactic drug
CN116135233A (en) Application of CPE in preparation of drugs for promoting in-situ neurogenesis and treating aging-related neurodegenerative diseases
Das Establishment of non-centrosomal microtubule organizing centers in skeletal muscle cells
Ni et al. Establishment and Characterization of SV40 T-Antigen Immortalized Porcine Muscle Satellite Cell

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant